However, there are targeted therapies for PIK3CA and BRAF driver mutations and mutations at PIK3CA or BRAF hotspots were detected in the AEC of six of the 11 lung cancer subjects and none of the non-cancer subjects (Table 4). This evidence concerns the gene BRAF and lung cancer.